4 results
Primary: To confirm that canakinumab 150 mg s.c. is superior to triamcinolone acetonide 40 mg i.m. with respect to patient*s assessment of gout pain intensity in the target joint at 72 hours post-dose (on a 0-100mm VAS). To confirm that canakinumabā¦
Primary: Longterm safety and tolerability.Secondary: Time to 1st flare, number and severity of flares, efficiacy in treating flares, effect on inflammatory markers, immunogenicity, PK.
Primary: Long term safety and tolerability.Secondary: Time to 1st flare, number and severity of flares, efficiacy in treating flares, effect on inflammatory markers, immunogenicity, PK.
Primary Objective- To evaluate immunogenicity of N9-GP (nonacog beta pegol)Secondary Objectives- To evaluate safety of N9-GP (nonacog beta pegol)- To evaluate efficacy of N9-GP (nonacog beta pegol) * in long-term prophylaxis treatment * in theā¦